ZNF143 interacts with p73 and is involved in cisplatin resistance through the transcriptional regulation of DNA repair genes

Oncogene

Volumn 26, Issue 36, 2007, Pages 5194-5203

  Wakasugi, T ^a   Izumi, H ^a   Uchiumi, T ^a   Suzuki, H ^a   Arao, T ^b   Nishio, K ^b   Kohno, K ^a  

^a UNIVERSITY OF OCCUPATIONAL AND ENVIRONMENTAL HEALTH   (Japan)

^b KINKI UNIVERSITY   (Japan)

Author keywords

Cisplatin; DNA repair; FEN 1; p73; Rad51; ZNF143

Indexed keywords

CISPLATIN; ETOPOSIDE; NUCLEIC ACID BINDING PROTEIN; OXALIPLATIN; PROTEIN P53; PROTEIN P73; UNCLASSIFIED DRUG; VINCRISTINE; ZINC FINGER PROTEIN 143;

ARTICLE; CONTROLLED STUDY; DNA DAMAGE; DNA MODIFICATION; DNA REPAIR; DRUG SENSITIVITY; GENE EXPRESSION; HUMAN; HUMAN CELL; MALE; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN BINDING; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN INTERACTION; TRANSCRIPTION REGULATION; TUMOR SUPPRESSOR GENE;

ANTINEOPLASTIC AGENTS; BASE SEQUENCE; CELL LINE, TUMOR; CISPLATIN; DNA PRIMERS; DNA REPAIR; DNA-BINDING PROTEINS; DRUG RESISTANCE, NEOPLASM; GENE EXPRESSION REGULATION; HUMANS; NUCLEAR PROTEINS; PROTEIN BINDING; TRANS-ACTIVATORS; TRANSCRIPTION, GENETIC; TUMOR SUPPRESSOR PROTEINS;

EID: 34547766645     PISSN: 09509232     EISSN: 14765594     Source Type: Journal    
DOI: 10.1038/sj.onc.1210326     Document Type: Article

References (31)

1. Altaha R, Liang X, Yu JJ, Reed E. (2004). Excision repair cross complementing-group 1: gene expression and platinum resistance. Int J Mol Med 14: 959-970.
2. Bhattacharyya A, Ear US, Koller BH, Weichselbaum RR, Bishop DK. (2000). The breast cancer susceptibility gene BRCA1 is required for subnuclear assembly of Rad51 and survival following treatment with the DNA cross-linking agent cisplatin. J Biol Chem 275: 23899-23903.
3. Chaney SG, Sancar A. (1996). DNA repair: enzymatic mechanisms and relevance to drug response. J Natl Cancer Inst 88: 1346-1360.
4. Cohen SM, Lippard SJ. (2001). Cisplatin: from DNA damage to cancer chemotherapy. Prog Nucleic Acid Res Mol Biol 67: 93-130.
5. De Laurenzi V, Costanzo A, Barcaroli D, Terrinoni A, Falco M, Annicchiarico-Petruzzelli M et al. (1998). Two new p73 splice variants, γ and δ, with different transcriptional activity. J Exp Med 188: 1763-1768.
6. Fujii R, Mutoh M, Niwa K, Yamada K, Aikou T, Nakagawa M et al. (1994). Active efflux system for cisplatin in cisplatinresistant human KB cells. Jpn J Cancer Res 85: 426-433.
7. Imamura T, Izumi H, Nagatani G, Ise T, Minoru N, Iwamoto Y et al. (2001). Interaction with p53 enhances binding of cisplatin-modified DNA by high mobility group 1 protein. J Biol Chem 276: 7534-7540.
8. Ise T, Nagatani G, Imamura T, Kato K, Takano H, Nomoto M et al. (1999). Transcription factor Y-Box binding protein 1 binds preferentially to cisplatin-modified DNA and interacts with proliferating cell nuclear antigen. Cancer Res 59: 342-346.
9. Ishiguchi H, Izumi H, Torigoe T, Yoshida Y, Kubota H, Tsuji S et al. (2004). ZNF143 activates gene expression in response to DNA damage and binds to cisplatin-modified DNA. Int J Cancer 111: 900-909.
10. Izumi H, Ohta R, Nagatani G, Ise T, Nakayama Y, Nomoto M et al. (2003). p300/CBP-associated factor (P/CAF) interacts with nuclear respiratory factor-1 to regulate the UDP-Nacetyl-alpha-D-galactosamine: polypeptide N-acetylgalactosaminyltransferase-3 gene. Biochem J 373: 713-722.
11. Keshelava N, Zuo JJ, Chen P, Waidyaratne SN, Luna MC, Gomer CJ et al. (2001). Loss of p53 function confers highlevel multidrug resistance in neuroblastoma cell lines. Cancer Res 61: 6185-6193.
12. Kohno K, Izumi H, Uchiumi T, Ashizuka T, Kuwano M. (2003). The pleiotropic functions of the Y-box-binding protein, YB-1. Bioessays 25: 691-698.
13. Kohno K, Uchiumi T, Niina I, Wakasugi T, Igarashi T, Momii Y et al. (2005). Transcription factors and drug resistance. Eur J Cancer 41: 2577-2586.
14. Kuwano M, Oda Y, Izumi H, Yang SJ, Uchiumi T, Iwamoto Y et al. (2004). The role of nuclear Y-box binding protein 1 as a global marker in drug resistance. Mol Cancer Ther 3: 1485-1492.
15. Lieber MR. (1997). The FEN-1 family of structure-specific nucleases in eukaryotic DNA replication, recombination and repair. Bioessays 19: 233-240.
16. Murakami T, Shibuya I, Ise T, Chen AS, Akiyama S, Nakagawa M et al. (2001). Elevated expression of vacuolar proton pump genes and cellular pH in cisplatin resistance. Int J Cancer 93: 869-874.
17. Myslinski E, Krol A, Carbon P. (1998). ZNF76 and ZNF143 are two human homologs of the transcriptional activator staf. J Biol Chem 34: 21998-22006.
18. Ohga T, Koike K, Ono M, Makino Y, Itagaki Y, Tanimoto M et al. (1996). Role of the human Y box-binding protein YB-1 in cellular sensitivity to the DNA-damaging agents cisplatin, mitomycin C, and ultraviolet light. Cancer Res 56: 4224-4228.
19. Raymond E, Faivre S, Chaney S, Woynarowski J, Cvitkovic E. (2002). Cellular and molecular pharmacology of oxaliplatin. Mol Cancer Ther 1: 227-235.
20. Rincon JC, Engler SK, Hargrove BW, Kunkel GR. (1998). Molecular cloning of a cDNA encoding human SPH-binding factor, a conserved protein that binds to the enhancer-like region of the U6 small nuclear RNA gene promoter. Nucleic Acids Res 26: 4846-4852.
21. Schaub M, Myslinski E, Schuster C, Krol A, Carbon P. (1997). Staf, a promiscuous activator for enhanced transcription by RNA polymerase II and III. EMBO J 16: 173-181.
22. Spiro C, McMurray CT. (2003). Nuclease-deficient FEN-1 blocks Rad51/BRCA1-mediated repair and causes trinucleotide repeat instability. Mol Cell Biol 23: 6063-6074.
23. Sugaya M, Takenoyama M, Osaki T, Yasuda M, Nagashima A, Sugio K et al. (2002). Establishment of 15 cancer cell lines from patients with lung cancer and the potential tools for immunotherapy. Chest 122: 282-288.
24. Tanabe M, Izumi H, Ise T, Higuchi S, Yamori T, Yasumoto K et al. (2003). Activating transcription factor 4 increases the cisplatin resistance of human cancer cell lines. Cancer Res 63: 8592-8595.
25. Tew KD. (1994). Glutathione-associated enzymes in anticancer drug resistance. Cancer Res 54: 4313-4320.
26. Torigoe T, Izumi H, Ishiguchi H, Yoichiro Y, Mizuho T, Takeshi Y et al. (2005). Cisplatin resistance and transcription factors. Curr Med Chem Anticancer Agents 5: 15-27.
27. Uramoto H, Izumi H, Ise T, Tada M, Uchiumi T, Kuwano M et al. (2002). p73 interacts with c-Myc to regulate Y-box-binding protein-1 expression. J Biol Chem 277: 31694-31702.
28. Uramoto H, Izumi H, Nagatani G, Ohmori H, Nahasue N, Ise T et al. (2003). Physical interaction of tumour suppressor p53/p73 with CCAAT-binding transcription factor 2 (CTF2) and differential regulation of human high-mobility group 1 (HMG1) gene expression. Biochem J 371: 301-310.
29. Vikhanskaya F, Marchini S, Marabese M, Galliera E, Broggini M. (2001). p73α overexpression is associated with resistance to treatment with DNA-damaging agents in a human ovarian cancer cell line. Cancer Res 61: 935-938.
30. Wood RD, Mitchell M, Lindahl T. (2005). Human DNA repair genes, 2005. Mut Res 577: 275-283.
31. Zamble DB, Lippard SJ. (1995). Cisplatin and DNA repair in cancer chemotherapy. Trends Biochem Sci 20: 435-439.